| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.3 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.13 | 0.3 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.047 | 0.3 |